WASHINGTON D.C. — America’s leading health insurance and pharmaceutical executives issued a stark, public ultimatum to Congress this week: cease attempts to protect patients from predatory billing practices, or face an immediate, unavoidable surge in health insurance premiums and drug costs. Industry leaders explained that new regulations designed to shield consumers from surprise medical bills and excessive pricing leave them no alternative but to pass "unforeseen operational adjustments" directly onto the American public.
"It truly pains us to threaten the financial stability and well-being of millions of Americans," stated Dr. Mortimer Van Der Bilge, CEO of OmniHealth Corp., from a gold-plated podium at the National Association of Healthcare Innovators (NAHI) annual gala. "But if Congress insists on limiting our ability to charge whatever the market will bear for life-saving treatments and essential services, we simply cannot maintain our current profit margins *and* keep premiums artificially low. The math, frankly, doesn't add up for our shareholders, who are, in their own way, suffering greatly from these regulatory encroachments."
The industry's position, meticulously outlined in a 300-page white paper titled "The Unintended Consequences of Empathy," argues that any law restricting corporate revenue streams inherently forces a counter-measure in the form of increased consumer burden. This includes, but is not limited to, higher co-pays, expanded deductibles, reduced coverage options, and a general recalibration of the 'customer experience' to reflect the grim realities of legislated altruism. "When you take away our ability to creatively innovate pricing structures," added Cassandra 'Cash' Flow, Chief Financial Officer of PharmaCorp International, "you’re essentially forcing us to innovate new ways to get that money back from the populace. It’s economics 101, really."
A recent study from the American Institute for Corporate Benevolence (AICB), a non-profit funded entirely by the pharmaceutical and insurance sectors, confirmed that every dollar saved by patients due to consumer protection laws directly correlates with a corporate decision to recover exactly that dollar, plus interest, from every other patient. "It's a zero-sum game," noted AICB Director Dr. Sterling Havisham, "where the sum is always positive for us, and the zero is, unfortunately, what's left in the average American's wallet."
Congress is expected to either immediately repeal all patient protection measures or publicly declare its full support for escalating health costs, thereby ensuring that legislative action will never again prioritize human health over quarterly earnings reports.
